The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of gemcitabine (G), cisplatin (C) with or without veliparib (V) (arms A, B) and a phase II single-arm study of single-agent veliparib (arm C) in patients with BRCA or PALB2-mutated pancreas adenocarcinoma (PC).
Eileen Mary O'Reilly
No relevant relationships to disclose
Maeve Aine Lowery
No relevant relationships to disclose
Kenneth H. Yu
No relevant relationships to disclose
Marinela Capanu
No relevant relationships to disclose
Zsofia Kinga Stadler
No relevant relationships to disclose
Andrew S. Epstein
No relevant relationships to disclose
Talia Golan
No relevant relationships to disclose
Amiel Segal
No relevant relationships to disclose
Michal Segal
No relevant relationships to disclose
Erin E. Salo-Mullen
No relevant relationships to disclose
Laura H. Tang
No relevant relationships to disclose
Ellen Hollywood
No relevant relationships to disclose
Mary Ellen Moynahan
No relevant relationships to disclose
Kinh G Do
No relevant relationships to disclose
Malcolm J. Moore
No relevant relationships to disclose
Hedy Lee Kindler
No relevant relationships to disclose
Robert J. Mayer
No relevant relationships to disclose
Alice P. Chen
No relevant relationships to disclose
David Paul Kelsen
No relevant relationships to disclose